- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | Zymeworks acquires struggling Theravance for $929M | ||
| Mo | FDA rejects Sobi's gout drug over manufacturing issues, sparing Amgen blockbuster | ||
| Mo | Look out, Amgen. Here comes Viridian with FDA nod for TED med Lumvoa | ||
| Fr | FDA slaps Dr. Reddy's Hyderabad biologics plant with seven observations in new Form 483 | ||
| Fr | Sanofi under antitrust probe as European Commission kicks off formal proceedings | ||
| Fr | Pharma's Cannes-do attitude sees industry return to triumph | ||
| Fr | Europe's CHMP reverses endorsement of Amgen's Tavneos as FDA hearing looms | ||
| Fr | Eli Lilly taps AI to bring personal memories to life during its European radio show road trip | ||
| Fr | Fierce Pharma Asia-Historic solid tumor CAR-T nod; Inside Pfizer, Innovent's $10B pact; More China deals | ||
| Fr | Biogen launches 'Ready for More' HD Spinraza campaign with a focus on how we see SMA | ||
| Fr | BeOne boosts support for Blood Cancer United with $5M commitment | ||
| Do | Bayer scores landmark victory as Supreme Court overturns Roundup verdict | ||
| Do | FDA shines harsh light on Pinnacle after finding fault with photodynamic therapy videos | ||
| Do | Merck KGaA throws down $11.3B for Bio-Techne in its biggest deal since 2015 Sigma-Aldrich buy | ||
| Do | Novartis teams up with Becoming rentABLE for its new SMA campaign | ||
| Do | Ionis scores transformational FDA label expansion for Tryngolza | ||
| Do | Jubilant HollisterStier gets FDA warning letter for quality control problems | ||
| Do | AstraZeneca spells out a community cancer screening strategy with the YMCA | ||
| Mi | Mapp, Gilead antivirals to be deployed in DRC Ebola trial: WHO chief | ||
| Mi | Pfizer scores 1st expansion in 7 years for breast cancer blockbuster Ibrance | ||
| Mi | Stada, under new CapVest ownership, picks up horde of European consumer brands | ||
| Mi | Lilly exec says MFN will affect company's obesity pill launch strategy in Europe: report | ||
| Mi | Amid safety concerns, ADC Therapeutics plots 17% staff cuts to push resources behind Zynlonta | ||
| Mi | Revance taps dancer Julianne Hough to choreograph social media push for Botox rival | ||
| 23.06. | Incyte drops lawsuit as CMS relents on classification of Opzelura |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.